ESSA Pharma Inc. (SEC Filing Page | XBRL Cloud Viewer | XBRL Instance)

Line Label Object Class Period Type Balance Report ElementName
1 001 - Document - Document and Entity Information Network

*

*

 http://www.essapharma.com/role/DocumentAndEntityInformation
2 Implied Table Table

*

*

 implied:Table
3 Document And Entity Information [Abstract] Abstract epi:DocumentAndEntityInformationAbstract
4 Entity Registrant Name Concept (Text/String) For Period dei:EntityRegistrantName
5 Entity Central Index Key Concept (CIK Number) For Period dei:EntityCentralIndexKey
6 Entity Current Reporting Status Concept (Yes/No) For Period dei:EntityCurrentReportingStatus
7 Entity Voluntary Filers Concept (Yes/No) For Period dei:EntityVoluntaryFilers
8 Current Fiscal Year End Date Concept (Month/Day) For Period dei:CurrentFiscalYearEndDate
9 Entity Filer Category Concept (Filer Category) For Period dei:EntityFilerCategory
10 Entity Emerging Growth Company Concept (Yes/No) For Period dei:EntityEmergingGrowthCompany
11 Entity Ex Transition Period Concept (Yes/No) For Period dei:EntityExTransitionPeriod
12 Entity Shell Company Concept (Yes/No) For Period dei:EntityShellCompany
13 Entity Well-Known Seasoned Issuer Concept (Yes/No) For Period dei:EntityWellKnownSeasonedIssuer
14 Entity Common Stock, Shares Outstanding Concept (Shares) As Of dei:EntityCommonStockSharesOutstanding
15 Document Type Concept (Submission Type) For Period dei:DocumentType
16 Document Period End Date Concept (Date) For Period dei:DocumentPeriodEndDate
17 Amendment Flag Concept (Yes/No) For Period dei:AmendmentFlag
18 Document Fiscal Year Focus Concept (Year) For Period dei:DocumentFiscalYearFocus
19 Document Fiscal Period Focus Concept (Fiscal Period) For Period dei:DocumentFiscalPeriodFocus
20 002 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION Network

*

*

 http://www.essapharma.com/role/ConsolidatedStatementsOfFinancialPosition
21 Implied Table Table

*

*

 implied:Table
22 Statement of financial position [abstract] Abstract ifrs-full:StatementOfFinancialPositionAbstract
23 ASSETS Abstract ifrs-full:AssetsAbstract
24 Current Abstract ifrs-full:CurrentAssetsAbstract
25 Cash Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
26 Receivables (Note 17) Concept (Monetary) As Of Debit epi:CurrentReceivablesFromTaxCreditsAndOther
27 Prepaids (Note 4) Concept (Monetary) As Of Debit ifrs-full:CurrentPrepaidExpenses
28 Total current assets Concept (Monetary) As Of Debit ifrs-full:CurrentAssets
29 Deposits Concept (Monetary) As Of Debit epi:NoncurrentDeposits
30 Equipment (Note 5) Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
31 Intangible assets (Note 6) Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsOtherThanGoodwill
32 Deferred financing costs (Note 9) Concept (Monetary) As Of Debit epi:DeferredFinancingCosts
33 Total assets Concept (Monetary) As Of Debit ifrs-full:Assets
34 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY) Abstract ifrs-full:EquityAndLiabilitiesAbstract
35 Current Abstract ifrs-full:CurrentLiabilitiesAbstract
36 Accounts payable and accrued liabilities Concept (Monetary) As Of Credit ifrs-full:TradeAndOtherCurrentPayables
37 Current portion of long-term debt (Note 7) Concept (Monetary) As Of Credit ifrs-full:CurrentPortionOfLongtermBorrowings
38 Income tax payable Concept (Monetary) As Of Credit ifrs-full:CurrentTaxLiabilitiesCurrent
39 Total current liabilities Concept (Monetary) As Of Credit ifrs-full:CurrentLiabilities
40 Long-term debt (Note 7) Concept (Monetary) As Of Credit ifrs-full:LongtermBorrowings
41 Derivative liabilities (Note 8) Concept (Monetary) As Of Credit ifrs-full:NoncurrentDerivativeFinancialLiabilities
42 Total liabilities Concept (Monetary) As Of Credit ifrs-full:Liabilities
43 Shareholders' equity (deficiency) Abstract ifrs-full:EquityAbstract
44 Share capital (Note 9) Concept (Monetary) As Of Credit ifrs-full:IssuedCapital
45 Reserves (Note 10) Concept (Monetary) As Of Credit ifrs-full:ReserveOfSharebasedPayments
46 Accumulated other comprehensive loss Concept (Monetary) As Of Credit ifrs-full:AccumulatedOtherComprehensiveIncome
47 Deficit Concept (Monetary) As Of Credit ifrs-full:RetainedEarnings
48 Total shareholders' equity (deficiency) Concept (Monetary) As Of Credit ifrs-full:Equity
49 Total liabilities and shareholders' equity (deficiency) Concept (Monetary) As Of Credit ifrs-full:EquityAndLiabilities
50 003 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS Network

*

*

 http://www.essapharma.com/role/ConsolidatedStatementsOfLossAndComprehensiveLoss
51 Implied Table Table

*

*

 implied:Table
52 Statement of profit or loss and other comprehensive income [abstract] Abstract ifrs-full:StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract
53 OPERATING EXPENSES Abstract epi:OperatingExpenseAbstract
54 Research and development, net of recoveries (Note 18) Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
55 Financing costs Concept (Monetary) For Period Debit ifrs-full:FinanceCosts
56 General and administration, net of recoveries (Note 18) Concept (Monetary) For Period Debit ifrs-full:GeneralAndAdministrativeExpense
57 Total operating expenses Concept (Monetary) For Period Debit ifrs-full:OperatingExpense
58 Foreign exchange Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
59 Interest income Concept (Monetary) For Period Credit ifrs-full:FinanceIncome
60 Loss of disposal of equipment (Note 5) Concept (Monetary) For Period Debit ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment
61 Gain on derivative liability (Note 8) Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
62 Net loss for the year before taxes Concept (Monetary) For Period Credit ifrs-full:ProfitLossBeforeTax
63 Income tax expense (Note 13) Concept (Monetary) For Period Debit ifrs-full:IncomeTaxExpenseContinuingOperations
64 Net loss for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
65 OTHER COMPREHENSIVE LOSS Abstract ifrs-full:OtherComprehensiveIncomeAbstract
66 Cumulative translation adjustment Concept (Monetary) For Period Credit ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
67 Comprehensive loss for the year Concept (Monetary) For Period Credit ifrs-full:ComprehensiveIncome
68 Basic and diluted loss per common share (in dollars per share) Concept (Share) For Period ifrs-full:BasicAndDilutedEarningsLossPerShare
69 Weighted average number of common shares outstanding - basic and diluted (in shares) Concept (Shares) For Period ifrs-full:WeightedAverageShares
70 004 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Network

*

*

 http://www.essapharma.com/role/ConsolidatedStatementsOfCashFlows
71 Implied Table Table

*

*

 implied:Table
72 Statement of cash flows [abstract] Abstract ifrs-full:StatementOfCashFlowsAbstract
73 CASH FLOWS FROM OPERATING ACTIVITIES Abstract ifrs-full:CashFlowsFromUsedInOperatingActivitiesAbstract
74 Loss for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
75 Items not affecting cash: Abstract ifrs-full:AdjustmentsForReconcileProfitLossAbstract
76 Amortization Concept (Monetary) For Period Debit epi:AmortizationExpenseOfTangibleAndIntangibleAssets
77 Gain on derivative liability Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
78 Finance expense Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForFinanceCosts
79 Product development and relocation grant Concept (Monetary) For Period Credit ifrs-full:RevenueFromGovernmentGrants
80 Unrealized foreign exchange Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
81 Share-based payments (Note 10) Concept (Monetary) For Period Debit ifrs-full:AdjustmentsForSharebasedPayments
82 Loss on disposal of equipment (Note 5) Concept (Monetary) For Period Debit ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment
83 Changes in non-cash working capital items: Abstract epi:ChangesInNonCashWorkingCapitalItemsAbstract
84 Receivables Concept (Monetary) For Period Debit epi:AdjustmentsForDecreaseIncreaseInCurrentReceivablesFromTaxCreditsAndOther
85 Prepaid expenses Concept (Monetary) For Period Debit epi:AdjustmentsForIncreaseDecreaseInPrepaidExpenses
86 Accounts payable and accrued liabilities Concept (Monetary) For Period Debit epi:AdjustmentsForIncreaseDecreaseInAccountPayableAndAccruedLiabilities
87 Income tax payable Concept (Monetary) For Period Credit ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
88 Net cash used in operating activities Concept (Monetary) For Period ifrs-full:CashFlowsFromUsedInOperatingActivities
89 CASH FLOWS FROM INVESTING ACTIVITIES Abstract ifrs-full:CashFlowsFromUsedInInvestingActivitiesAbstract
90 Acquisition of equipment Concept (Monetary) For Period Credit ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
91 Deposits Concept (Monetary) For Period Debit epi:DepositsClassifiedAsInvestingActivities
92 Net cash used in investing activities Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInInvestingActivities
93 CASH FLOWS FROM FINANCING ACTIVITIES Abstract ifrs-full:CashFlowsFromUsedInFinancingActivitiesAbstract
94 Advance on product development and relocation grant Concept (Monetary) For Period Debit epi:ProceedsAdvanceOnProductDevelopmentAndRelocationGrant
95 Proceeds on financing Concept (Monetary) For Period Debit epi:ProceedsOnEquityFinancing
96 Share issuance costs Concept (Monetary) For Period Credit ifrs-full:PaymentsForShareIssueCosts
97 Proceeds on loan advance Concept (Monetary) For Period Debit ifrs-full:ProceedsFromNoncurrentBorrowings
98 Financing costs Concept (Monetary) For Period Credit epi:RepaymentsOfFinancingCosts
99 Loan principal repaid Concept (Monetary) For Period Credit ifrs-full:RepaymentsOfNoncurrentBorrowings
100 Interest paid Concept (Monetary) For Period Credit ifrs-full:InterestPaidClassifiedAsFinancingActivities
101 Options exercised Concept (Monetary) For Period Debit ifrs-full:ProceedsFromExerciseOfOptions
102 Warrants exercised Concept (Monetary) For Period Debit epi:ProceedsFromExercisedWarrants
103 Net cash provided by financing activities Concept (Monetary) For Period Debit ifrs-full:CashFlowsFromUsedInFinancingActivities
104 Effect of foreign exchange on cash Concept (Monetary) For Period Debit ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
105 Change in cash for the year Concept (Monetary) For Period Debit ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
106 Cash, beginning of year Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
107 Cash, end of year Concept (Monetary) As Of Debit ifrs-full:CashAndCashEquivalents
108 005 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY) Network

*

*

 http://www.essapharma.com/role/ConsolidatedStatementOfChangesInShareholdersEquityDeficiency
109 Statement of changes in equity [table] Table

*

*

 ifrs-full:StatementOfChangesInEquityTable
110 Components of equity [axis] Axis ifrs-full:ComponentsOfEquityAxis
111 Equity [member] Member ifrs-full:EquityMember
112 Deficit Member ifrs-full:RetainedEarningsMember
113 Cumulative translation adjustment Member ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember
114 Reserves Warrants Member epi:ReservesWarrantsMember
115 Reserves Share-based payments Member ifrs-full:ReserveOfSharebasedPaymentsMember
116 Special warrants Member epi:SpecialWarrantsMember
117 Preferred shares Member ifrs-full:PreferenceSharesMember
118 Share capital Member ifrs-full:IssuedCapitalMember
119 Statement of changes in equity [line items] LineItems ifrs-full:StatementOfChangesInEquityLineItems
120 Balance, beginning Concept (Monetary) As Of Credit ifrs-full:Equity
121 Balance, beginning (in shares) Concept (Shares) As Of ifrs-full:NumberOfSharesIssued
122 Financing Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
123 Financing (in shares) Concept (Shares) For Period epi:IncreaseDecreaseThroughTransactionsWithOwnersShares
124 Private placement Concept (Monetary) For Period Credit epi:IncreaseThroughIssuanceOfSpecialWarrantsInPrivatePlacementEquity
125 Private placement (in shares) Concept (Shares) For Period epi:IncreaseThroughCommonSharesIssuedInPrivatePlacementEquity
126 Issuance costs Concept (Monetary) For Period Debit ifrs-full:ShareIssueRelatedCost
127 Number Of Share Issue Related Cost Concept (Shares) For Period epi:NumberOfShareIssueRelatedCost
128 Issuance costs Concept (Monetary) For Period Debit epi:SpecialWarrantsIssuanceCosts2
129 Options exercised Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
130 Options exercised (in shares) Concept (Shares) For Period epi:IncreaseDecreaseThroughExerciseOfOptionsShares
131 Warrants exercised Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
132 Warrants exercised (in shares) Concept (Shares) For Period epi:IncreaseDecreaseThroughExerciseOfWarrantsEquityShares
133 Share-based payments Concept (Monetary) For Period Credit ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
134 Foreign currency adjustment Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
135 Effect of functional currency change Concept (Monetary) For Period Credit epi:IncreaseDecreaseThroughEffectOfFunctionalCurrencyChange
136 Loss for the year Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
137 Balance, ending Concept (Monetary) As Of Credit ifrs-full:Equity
138 Balance, beginning (in shares) Concept (Shares) As Of ifrs-full:NumberOfSharesIssued
139 006 - Disclosure - NATURE AND CONTINUANCE OF OPERATIONS Network

*

*

 http://www.essapharma.com/role/NatureAndContinuanceOfOperations
140 Implied Table Table

*

*

 implied:Table
141 Nature And Continuance Of Operations [Abstract] Abstract epi:NatureAndContinuanceOfOperationsAbstract
142 NATURE AND CONTINUANCE OF OPERATIONS Concept (Text Block (HTML)) For Period epi:NatureAndContinuanceOfOperationsTextBlock
143 007 - Disclosure - BASIS OF PRESENTATION Network

*

*

 http://www.essapharma.com/role/BasisOfPresentation
144 Implied Table Table

*

*

 implied:Table
145 Disclosure Of Basis Of Presentation [Abstract] Abstract epi:DisclosureOfBasisOfPresentationAbstract
146 BASIS OF PRESENTATION Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
147 008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Network

*

*

 http://www.essapharma.com/role/SignificantAccountingPolicies
148 Implied Table Table

*

*

 implied:Table
149 Significant Accounting Policies [Abstract] Abstract epi:SignificantAccountingPoliciesAbstract
150 SIGNIFICANT ACCOUNTING POLICIES Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory
151 009 - Disclosure - PREPAID EXPENSES Network

*

*

 http://www.essapharma.com/role/PrepaidExpenses
152 Implied Table Table

*

*

 implied:Table
153 Current prepayments [abstract] Abstract ifrs-full:CurrentPrepaymentsAbstract
154 PREPAID EXPENSES Concept (Text Block (HTML)) For Period epi:PrepaidExpensesTextBlock
155 010 - Disclosure - EQUIPMENT Network

*

*

 http://www.essapharma.com/role/Equipment
156 Implied Table Table

*

*

 implied:Table
157 Property, plant and equipment [abstract] Abstract ifrs-full:PropertyPlantAndEquipmentAbstract
158 EQUIPMENT Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
159 011 - Disclosure - INTANGIBLE ASSETS Network

*

*

 http://www.essapharma.com/role/IntangibleAssets
160 Implied Table Table

*

*

 implied:Table
161 Disclosure of detailed information about intangible assets [abstract] Abstract ifrs-full:DisclosureOfIntangibleAssetsAbstract
162 INTANGIBLE ASSETS Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIntangibleAssetsExplanatory
163 012 - Disclosure - LONG-TERM DEBT Network

*

*

 http://www.essapharma.com/role/LongTermDebt
164 Implied Table Table

*

*

 implied:Table
165 Disclosure of detailed information about borrowings [abstract] Abstract ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsAbstract
166 LONG-TERM DEBT Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory
167 013 - Disclosure - DERIVATIVE LIABILITIES Network

*

*

 http://www.essapharma.com/role/DerivativeLiabilities
168 Implied Table Table

*

*

 implied:Table
169 Disclosure of financial liabilities [abstract] Abstract ifrs-full:DisclosureOfFinancialLiabilitiesAbstract
170 DERIVATIVE LIABILITIES Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory
171 014 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIENCY) Network

*

*

 http://www.essapharma.com/role/ShareholdersEquityDeficiency
172 Implied Table Table

*

*

 implied:Table
173 Disclosure Of Share Capital Preference Shares And Special Warrants [Abstract] Abstract epi:DisclosureOfShareCapitalPreferenceSharesAndSpecialWarrantsAbstract
174 SHAREHOLDERS' EQUITY (DEFICIENCY) Concept (Text Block (HTML)) For Period epi:DisclosureOfShareCapitalPreferenceSharesAndSpecialWarrantsTextBlock
175 015 - Disclosure - RESERVES Network

*

*

 http://www.essapharma.com/role/Reserves
176 Implied Table Table

*

*

 implied:Table
177 Disclosure of reserves within equity [abstract] Abstract ifrs-full:DisclosureOfReservesWithinEquityAbstract
178 RESERVES Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory
179 016 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS Network

*

*

 http://www.essapharma.com/role/SupplementalDisclosureWithRespectToCashFlows
180 Implied Table Table

*

*

 implied:Table
181 Disclosure of reconciliation of liabilities arising from financing activities [abstract] Abstract ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesAbstract
182 SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCashFlowStatementExplanatory
183 017 - Disclosure - RELATED PARTY TRANSACTIONS Network

*

*

 http://www.essapharma.com/role/RelatedPartyTransactions
184 Implied Table Table

*

*

 implied:Table
185 Related party transactions [abstract] Abstract ifrs-full:RelatedPartyTransactionsAbstract
186 RELATED PARTY TRANSACTIONS Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfRelatedPartyExplanatory
187 018 - Disclosure - INCOME TAXES Network

*

*

 http://www.essapharma.com/role/IncomeTaxes
188 Implied Table Table

*

*

 implied:Table
189 Income Taxes [Abstract] Abstract epi:IncomeTaxesAbstract
190 INCOME TAXES Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIncomeTaxExplanatory
191 019 - Disclosure - SEGMENTED INFORMATION Network

*

*

 http://www.essapharma.com/role/SegmentedInformation
192 Implied Table Table

*

*

 implied:Table
193 Disclosure of operating segments [abstract] Abstract ifrs-full:DisclosureOfOperatingSegmentsAbstract
194 SEGMENTED INFORMATION Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory
195 020 - Disclosure - CAPITAL MANAGEMENT Network

*

*

 http://www.essapharma.com/role/CapitalManagement
196 Implied Table Table

*

*

 implied:Table
197 Disclosure of objectives, policies and processes for managing capital [abstract] Abstract ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalAbstract
198 CAPITAL MANAGEMENT Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory
199 021 - Disclosure - FINANCIAL INSTRUMENTS AND RISK Network

*

*

 http://www.essapharma.com/role/FinancialInstrumentsAndRisk
200 Implied Table Table

*

*

 implied:Table
201 Disclosure of detailed information about financial instruments [abstract] Abstract ifrs-full:DisclosureOfFinancialInstrumentsAbstract
202 FINANCIAL INSTRUMENTS AND RISK Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
203 022 - Disclosure - COMMITMENTS Network

*

*

 http://www.essapharma.com/role/Commitments
204 Implied Table Table

*

*

 implied:Table
205 Commitments [Abstract] Abstract epi:CommitmentsAbstract
206 COMMITMENTS Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfCommitmentsExplanatory
207 023 - Disclosure - EXPENSES BY NATURE Network

*

*

 http://www.essapharma.com/role/ExpensesByNature
208 Implied Table Table

*

*

 implied:Table
209 Expenses by nature [abstract] Abstract ifrs-full:ExpenseByNatureAbstract
210 EXPENSES BY NATURE Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfExpensesByNatureExplanatory
211 024 - Disclosure - SUBSEQUENT EVENTS Network

*

*

 http://www.essapharma.com/role/SubsequentEvents
212 Implied Table Table

*

*

 implied:Table
213 Disclosure of non-adjusting events after reporting period [abstract] Abstract ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract
214 SUBSEQUENT EVENTS Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
215 025 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Network

*

*

 http://www.essapharma.com/role/SignificantAccountingPoliciesPolicies
216 Implied Table Table

*

*

 implied:Table
217 Disclosure Of Significant Accounting Policies [Abstract] Abstract epi:DisclosureOfSignificantAccountingPoliciesAbstract
218 Foreign exchange Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
219 Equipment Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory
220 Intangible assets Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory
221 Impairment of long-lived assets Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory
222 Provisions Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory
223 Government assistance Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants
224 Research and development costs Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
225 Financial instruments Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory
226 Embedded derivatives Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory
227 Preferred shares Concept (Text Block (HTML)) For Period epi:DescriptionOfAccountingPolicyForPreferredSharesPolicyTextBlock
228 Share-based payments Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
229 Basic and diluted loss per share Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
230 Income taxes Concept (Text Block (HTML)) For Period ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory
231 New standards not yet adopted Concept (Text Block (HTML)) For Period epi:DescriptionOfAccountingPolicyForNewStandardsNotYetAdoptedPolicyTextBlock
232 026 - Disclosure - PREPAID EXPENSES (Tables) Network

*

*

 http://www.essapharma.com/role/Prepaidexpensestables
233 Implied Table Table

*

*

 implied:Table
234 Current prepayments [abstract] Abstract ifrs-full:CurrentPrepaymentsAbstract
235 Schedule of prepaid expenses Concept (Text Block (HTML)) For Period epi:ScheduleOfPrepaidExpensesTableTextBlock
236 027 - Disclosure - EQUIPMENT (Tables) Network

*

*

 http://www.essapharma.com/role/EquipmentTables
237 Implied Table Table

*

*

 implied:Table
238 Property, plant and equipment [abstract] Abstract ifrs-full:PropertyPlantAndEquipmentAbstract
239 Schedule of equipment Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
240 028 - Disclosure - INTANGIBLE ASSETS (Tables) Network

*

*

 http://www.essapharma.com/role/IntangibleAssetsTables
241 Implied Table Table

*

*

 implied:Table
242 Disclosure of detailed information about intangible assets [abstract] Abstract ifrs-full:DisclosureOfIntangibleAssetsAbstract
243 Schedule of intangible assets Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory
244 029 - Disclosure - LONG-TERM DEBT (Tables) Network

*

*

 http://www.essapharma.com/role/LongTermDebtTables
245 Implied Table Table

*

*

 implied:Table
246 Disclosure of detailed information about borrowings [abstract] Abstract ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsAbstract
247 Schedule of long-term debt Concept (Text Block (HTML)) For Period epi:ScheduleOfLongTermDebtTableTextBlock
248 030 - Disclosure - DERIVATIVE LIABILITIES (Tables) Network

*

*

 http://www.essapharma.com/role/DERIVATIVELIABILITIESTables
249 Implied Table Table

*

*

 implied:Table
250 Disclosure of financial liabilities [abstract] Abstract ifrs-full:DisclosureOfFinancialLiabilitiesAbstract
251 Schedule of fair value of the derivative warrant liabilities on initial recognition and reporting/remeasurement dates Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory
252 Schedule of changes to derivative liabilities Concept (Text Block (HTML)) For Period epi:ScheduleOfChangesToDerivativeLiabilitiesTableTextBlock
253 031 - Disclosure - RESERVES (Tables) Network

*

*

 http://www.essapharma.com/role/RESERVESTables
254 Implied Table Table

*

*

 implied:Table
255 Other Equity Reserves [Abstract] Abstract epi:OtherEquityReservesAbstract
256 Schedule of stock option transactions Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory
257 Schedule of options outstanding enabling holders to acquire common shares Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory
258 Schedule of options granted and vesting with allocations to functional expense Concept (Text Block (HTML)) For Period epi:ScheduleOfCompensationCostForShareBasedPaymentArrangementAllocationOfShareBasedCompensationCostsTableTextBlock
259 Schedule of weighted average assumptions used for Black-Scholes option-pricing model valuation of stock options granted Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory
260 Schedule of warrant transactions Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
261 Schedule of warrants outstanding enabling holders to acquire common shares Concept (Text Block (HTML)) For Period epi:DisclosureOfNumberAndWeightedAverageExercisePricesWithExpiryDateOfOtherEquityInstrumentsOutstandingTableTextBlock
262 032 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) Network

*

*

 http://www.essapharma.com/role/RELATEDPARTYTRANSACTIONSTables
263 Implied Table Table

*

*

 implied:Table
264 Related party transactions [abstract] Abstract ifrs-full:RelatedPartyTransactionsAbstract
265 Schedule of compensation paid to key management personnel Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory
266 033 - Disclosure - INCOME TAXES (Tables) Network

*

*

 http://www.essapharma.com/role/INCOMETAXESTables
267 Implied Table Table

*

*

 implied:Table
268 Income Taxes [Abstract] Abstract epi:IncomeTaxesAbstract
269 Schedule of reconciliation of income taxes at statutory rates Concept (Text Block (HTML)) For Period epi:ScheduleOfIncomeTaxRateReconciliationTableTextBlock
270 Schedule of unrecognized temporary tax differences Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
271 034 - Disclosure - COMMITMENTS (Tables) Network

*

*

 http://www.essapharma.com/role/COMMITMENTSTables
272 Implied Table Table

*

*

 implied:Table
273 Commitments [Abstract] Abstract epi:CommitmentsAbstract
274 Schedule of commitments Concept (Text Block (HTML)) For Period epi:ScheduleOfCommitmentsTableTextBlock
275 035 - Disclosure - EXPENSES BY NATURE (Tables) Network

*

*

 http://www.essapharma.com/role/EXPENSESBYNATURETables
276 Implied Table Table

*

*

 implied:Table
277 Expenses by nature [abstract] Abstract ifrs-full:ExpenseByNatureAbstract
278 Schedule of Research and development expenses Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory
279 Schedule of General and administrative expenses Concept (Text Block (HTML)) For Period ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory
280 036 - Disclosure - NATURE AND CONTINUANCE OF OPERATIONS (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/NatureAndContinuanceOfOperationsDetailTextuals
281 Implied Table Table

*

*

 implied:Table
282 Nature And Continuance Of Operations [Abstract] Abstract epi:NatureAndContinuanceOfOperationsAbstract
283 Reverse stock split, conversion ratio Concept (Pure) For Period epi:ReverseStockSplitConversionRatio
284 Net loss Concept (Monetary) For Period Credit ifrs-full:ProfitLoss
285 Accumulated deficit Concept (Monetary) As Of Credit ifrs-full:RetainedEarnings
286 Gross proceeds on sale of common shares Concept (Monetary) For Period Debit epi:ProceedsOnEquityFinancing
287 037 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/SignificantAccountingPoliciesDetailTextuals
288 Disclosure of detailed information about property, plant and equipment [table] Table

*

*

 ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable
289 Classes of property, plant and equipment [axis] Axis ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis
290 Property, plant and equipment [member] Member ifrs-full:PropertyPlantAndEquipmentMember
291 Computer equipment Member ifrs-full:ComputerEquipmentMember
292 Office equipment Member ifrs-full:OfficeEquipmentMember
293 Disclosure of detailed information about property, plant and equipment [line items] LineItems ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems
294 Percentage of depreciation Concept (Percent) For Period epi:PercentageOfDepreciation
295 Depreciation method Concept (Text/String) For Period ifrs-full:DepreciationMethodPropertyPlantAndEquipment
296 038 - Disclosure - PREPAID EXPENSES (Details) Network

*

*

 http://www.essapharma.com/role/PREPAIDEXPENSESDetails
297 Implied Table Table

*

*

 implied:Table
298 Current prepayments [abstract] Abstract ifrs-full:CurrentPrepaymentsAbstract
299 Clinical program deposit Concept (Monetary) As Of Debit epi:ClinicalProgramDepositPrepraidExpenses
300 Prepaid insurance Concept (Monetary) As Of Debit epi:PrepaidInsuranceExpense
301 Other deposits and prepaid expenses Concept (Monetary) As Of Debit epi:OtherDepositsAndPrepaidExpenses
302 Balance Concept (Monetary) As Of Debit ifrs-full:CurrentPrepaidExpenses
303 039 - Disclosure - EQUIPMENT (Details) Network

*

*

 http://www.essapharma.com/role/EquipmentDetails
304 Disclosure of detailed information about property, plant and equipment [table] Table

*

*

 ifrs-full:DisclosureOfPropertyPlantAndEquipmentTable
305 Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Axis ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis
306 Carrying amount [member] Member ifrs-full:CarryingAmountMember
307 Cost Member ifrs-full:GrossCarryingAmountMember
308 Accumulated Amortization Member ifrs-full:AccumulatedDepreciationAndAmortisationMember
309 Classes of property, plant and equipment [axis] Axis ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis
310 Property, plant and equipment [member] Member ifrs-full:PropertyPlantAndEquipmentMember
311 Furniture and fixtures Member ifrs-full:FixturesAndFittingsMember
312 Computer equipment Member ifrs-full:ComputerEquipmentMember
313 Disclosure of detailed information about property, plant and equipment [line items] LineItems ifrs-full:DisclosureOfPropertyPlantAndEquipmentLineItems
314 Balance Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
315 Amortization expense Concept (Monetary) For Period Debit epi:AmortizationExpenseForTangibleAssets
316 Disposals Concept (Monetary) For Period Credit ifrs-full:DisposalsPropertyPlantAndEquipment
317 Balance Concept (Monetary) As Of Debit ifrs-full:PropertyPlantAndEquipment
318 040 - Disclosure - EQUIPMENT (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/EquipmentDetailTextuals
319 Implied Table Table

*

*

 implied:Table
320 Property, plant and equipment [abstract] Abstract ifrs-full:PropertyPlantAndEquipmentAbstract
321 Proceeds from disposal of equipment Concept (Monetary) For Period Debit ifrs-full:ProceedsFromDisposalsOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets
322 Loss on disposal of equipment (Note 5) Concept (Monetary) For Period Debit ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment
323 041 - Disclosure - INTANGIBLE ASSETS (Details) Network

*

*

 http://www.essapharma.com/role/INTANGIBLEASSETSDetails
324 Disclosure of detailed information about intangible assets [table] Table

*

*

 ifrs-full:DisclosureOfIntangibleAssetsTable
325 Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Axis ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis
326 Carrying amount [member] Member ifrs-full:CarryingAmountMember
327 Cost Member ifrs-full:GrossCarryingAmountMember
328 Accumulated Amortization Member ifrs-full:AccumulatedDepreciationAndAmortisationMember
329 Classes of intangible assets and goodwill [axis] Axis ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis
330 Intangible assets and goodwill [member] Member ifrs-full:IntangibleAssetsAndGoodwillMember
331 NTD Technology Member ifrs-full:TechnologybasedIntangibleAssetsMember
332 Disclosure of detailed information about intangible assets [line items] LineItems ifrs-full:DisclosureOfIntangibleAssetsLineItems
333 Balance Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsOtherThanGoodwill
334 Amortization expense Concept (Monetary) For Period Debit ifrs-full:AmortisationExpense
335 Balance Concept (Monetary) As Of Debit ifrs-full:IntangibleAssetsOtherThanGoodwill
336 042 - Disclosure - INTANGIBLE ASSETS (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/IntangibleAssetsDetailTextuals
337 Disclosure of detailed information about intangible assets [table] Table

*

*

 ifrs-full:DisclosureOfIntangibleAssetsTable
338 Type Of Arrangement And Non-Arrangement Transaction [Axis] Axis epi:TypeOfArrangementAndNon-ArrangementTransactionAxis
339 Arrangements And Non-Arrangement Transaction [Domain] Member epi:ArrangementsAndNon-ArrangementTransactionDomain
340 License Agreement Member epi:LicenseAgreementMember
341 Classes of intangible assets and goodwill [axis] Axis ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis
342 Intangible assets and goodwill [member] Member ifrs-full:IntangibleAssetsAndGoodwillMember
343 NTD Technology Member ifrs-full:TechnologybasedIntangibleAssetsMember
344 Disclosure of detailed information about intangible assets [line items] LineItems ifrs-full:DisclosureOfIntangibleAssetsLineItems
345 Minimum advance royalty payments Concept (Monetary) For Period Credit epi:MinimumAdvanceRoyaltyPayments
346 Total amount of milestone payments after start of a Phase II clinical trial Concept (Monetary) For Period Credit epi:AmountOfMilestonePaymentsAtStartOfSecondPhaseClinicalTrial
347 Total amount of milestone payments after start of a Phase III clinical trial Concept (Monetary) For Period Credit epi:AmountOfMilestonePaymentsAtStartOfThirdPhaseClinicalTrial
348 Total amount of milestone payments at application for marketing approval Concept (Monetary) For Period Credit epi:AmountOfMilestonePaymentsAtApplicationForMarketingApproval
349 043 - Disclosure - LONG-TERM DEBT (Details) Network

*

*

 http://www.essapharma.com/role/LONGTERMDEBTDetails
350 Implied Table Table

*

*

 implied:Table
351 Disclosure of detailed information about borrowings [abstract] Abstract ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsAbstract
352 Borrowings [Roll Forward] Abstract epi:BorrowingsRollForward
353 Balance Concept (Monetary) As Of Credit epi:BorrowingsLessUnaccretedTransactionCosts
354 Loan advance Concept (Monetary) For Period Debit ifrs-full:ProceedsFromNoncurrentBorrowings
355 Transaction costs Concept (Monetary) For Period Debit epi:TransactionCostsOfBorrowings
356 Principal repaid Concept (Monetary) For Period Credit ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
357 Interest paid Concept (Monetary) For Period Credit ifrs-full:InterestPaidClassifiedAsFinancingActivities
358 Accretion Concept (Monetary) For Period Debit epi:AccretionCost
359 Balance Concept (Monetary) As Of Credit epi:BorrowingsLessUnaccretedTransactionCosts
360 Current portion Concept (Monetary) As Of Credit ifrs-full:CurrentPortionOfLongtermBorrowings
361 Long-term portion Concept (Monetary) As Of Credit ifrs-full:LongtermBorrowings
362 044 - Disclosure - LONG-TERM DEBT (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/LongTermDebtDetailTextuals
363 Disclosure of detailed information about borrowings [table] Table

*

*

 ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsTable
364 Tranche [Axis] Axis epi:TrancheAxis
365 Tranche [Domain] Member epi:TrancheDomain
366 Third and final tranche Member epi:ThirdAndFinalTrancheMember
367 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
368 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
369 SVB Term Loan Member epi:TermLoanCreditFacilityMember
370 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
371 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
372 Silicon Valley Bank ("SVB") Member epi:SiliconValleyBankMember
373 Disclosure of detailed information about borrowings [line items] LineItems ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsLineItems
374 Maximum borrowing capacity of capital term loan facility Concept (Monetary) As Of Credit epi:CreditFacilityMaximumBorrowingCapacity
375 Drawn down from SVB Term Loan Concept (Monetary) For Period Debit ifrs-full:ProceedsFromNoncurrentBorrowings
376 Conditional option to receive upon positive data for clinical trial and CPRIT grant Concept (Monetary) For Period Credit epi:ConditionalOptionToReceiveUponPositiveDataForClinicalTrialAndCpritGrant
377 045 - Disclosure - LONG-TERM DEBT (Detail Textuals 1) Network

*

*

 http://www.essapharma.com/role/LongTermDebtDetailTextuals1
378 Disclosure of detailed information about borrowings [table] Table

*

*

 ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsTable
379 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
380 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
381 SVB Term Loan Member epi:TermLoanCreditFacilityMember
382 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
383 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
384 Silicon Valley Bank ("SVB") Member epi:SiliconValleyBankMember
385 Disclosure of detailed information about borrowings [line items] LineItems ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsLineItems
386 Description of variable rate basis Concept (Text/String) For Period ifrs-full:BorrowingsInterestRateBasis
387 Additional basis spread on variable rate Concept (Percent) As Of ifrs-full:BorrowingsAdjustmentToInterestRateBasis
388 Maturity date Concept (Date) For Period epi:BorrowingsMaturityDate
389 Percentage of loan amount due as a final payment Concept (Percent) For Period epi:PercentageOfFinalPaymentOfLoanAmountAdvanced
390 046 - Disclosure - LONG-TERM DEBT (Detail Textuals 2) Network

*

*

 http://www.essapharma.com/role/LongTermDebtDetailTextuals2
391 Disclosure of detailed information about borrowings [table] Table

*

*

 ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsTable
392 Arrangements And Non-Arrangement Transactions [Axis] Axis epi:ArrangementsAndNon-ArrangementTransactionsAxis
393 Type Of Arrangement [Member] Member epi:TypeOfArrangementMember
394 Term credit loan facility agreement Member epi:TermCreditLoanFacilityAgreementMember
395 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
396 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
397 Silicon Valley Bank ("SVB") Member epi:SiliconValleyBankMember
398 Disclosure of detailed information about borrowings [line items] LineItems ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsLineItems
399 Number of warrants granted Concept (Shares) For Period epi:NumberOfWarrantsGranted
400 Exercise price of warrants Concept (Share) For Period epi:ExercisePriceOfWarrants
401 Term of warrants Concept (xbrli:durationItemType) For Period epi:TermOfWarrants
402 Fair value assigned to warrants issued Concept (Monetary) As Of Debit ifrs-full:CreditDerivativeFairValue
403 Additional transaction costs Concept (Monetary) For Period Debit epi:AdditionalTransactionCosts
404 Effective interest rate on borrowings Concept (Percent) As Of ifrs-full:BorrowingsInterestRate
405 047 - Disclosure - DERIVATIVE LIABILITIES (Details) Network

*

*

 http://www.essapharma.com/role/DERIVATIVELIABILITIESDetails
406 Disclosure of financial liabilities [table] Table

*

*

 ifrs-full:DisclosureOfFinancialLiabilitiesTable
407 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
408 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
409 2016 Warrants Member epi:Warrants2016Member
410 Broker Warrants Denominated in Foreign Currency Member epi:BrokerWarrantsMember
411 SVB Warrants Member epi:SvbWarrantsMember
412 Disclosure of financial liabilities [line items] LineItems ifrs-full:DisclosureOfFinancialLiabilitiesLineItems
413 Risk-free interest rate Concept (Percent) For Period epi:RiskFreeInterestRateWarrantsIssued
414 Expected life Concept (xbrli:durationItemType) For Period epi:WarrantLifeWarrantsIssued
415 Expected annualized volatility Concept (Percent) For Period ifrs-full:HistoricalVolatilityForSharesSignificantUnobservableInputsLiabilities
416 Dividend Concept (Percent) For Period epi:ExpectedDividendAsPercentageWarrants
417 048 - Disclosure - DERIVATIVE LIABILITIES (Details 1) Network

*

*

 http://www.essapharma.com/role/DERIVATIVELIABILITIESDetails1
418 Implied Table Table

*

*

 implied:Table
419 Disclosure of financial liabilities [abstract] Abstract ifrs-full:DisclosureOfFinancialLiabilitiesAbstract
420 Balance Concept (Monetary) As Of Credit ifrs-full:DerivativeFinancialLiabilities
421 Derivative liability on issuance of warrants Concept (Monetary) For Period Credit epi:DerivativeFinancialLiabilitiesIssueOfWarrants
422 Change in fair value Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
423 Balance Concept (Monetary) As Of Credit ifrs-full:DerivativeFinancialLiabilities
424 Derivatives with expected life of less than one year Concept (Monetary) As Of Credit ifrs-full:CurrentDerivativeFinancialLiabilities
425 Derivatives with expected life greater than one year Concept (Monetary) As Of Credit ifrs-full:NoncurrentDerivativeFinancialLiabilities
426 049 - Disclosure - DERIVATIVE LIABILITIES (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/DerivativeLiabilitiesDetailTextuals
427 Disclosure of financial liabilities [table] Table

*

*

 ifrs-full:DisclosureOfFinancialLiabilitiesTable
428 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
429 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
430 Broker Warrants Member epi:BrokerWarrantsMember
431 Disclosure of financial liabilities [line items] LineItems ifrs-full:DisclosureOfFinancialLiabilitiesLineItems
432 Number of warrants issued Concept (Shares) For Period epi:NumberOfWarrantIssued
433 Exercise price of warrants Concept (Share) For Period epi:ExercisePriceOfWarrants
434 Derivative financial liabilities Concept (Monetary) As Of Credit ifrs-full:DerivativeFinancialLiabilities
435 Derivative liability fair value Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilitiesAtFairValue
436 Risk-free interest rate Concept (Percent) For Period epi:RiskFreeInterestRateWarrantsIssued
437 Expected life Concept (xbrli:durationItemType) For Period epi:WarrantLifeWarrantsIssued
438 Expected annualized volatility Concept (Percent) For Period ifrs-full:HistoricalVolatilityForSharesSignificantUnobservableInputsLiabilities
439 Dividend Concept (Percent) For Period epi:ExpectedDividendAsPercentageWarrants
440 De-recognized the derivative liability Concept (Monetary) For Period epi:DerecognizedDerivativeLiability
441 Number of remaining outstanding warrants expired unexercised Concept (Shares) For Period epi:NumberOfRemainingOutstandingWarrantsExpiredUnexercised
442 Amount of issuance of a convertible debenture Concept (Monetary) As Of Credit epi:ConvertibleDebentures
443 Term of warrants Concept (xbrli:durationItemType) For Period epi:TermOfWarrants
444 Amount of derivative liability change in fair value Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
445 Warrant issued in connection with issuance of convertible debt Concept (Monetary) For Period Credit epi:ValueOfWarrantsIssuedInConnectionWithIssuanceOfConvertibleDebt
446 050 - Disclosure - DERIVATIVE LIABILITIES (Detail Textuals 1) Network

*

*

 http://www.essapharma.com/role/DerivativeLiabilitiesDetailTextuals1
447 Disclosure of financial liabilities [table] Table

*

*

 ifrs-full:DisclosureOfFinancialLiabilitiesTable
448 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
449 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
450 2016 Warrants Member epi:Warrants2016Member
451 7 year warrants Member epi:SevenYearWarrantsMember
452 2 year warrants Member epi:TwoYearWarrantsMember
453 2 year warrants and 7 year warrants Member epi:TwoYearWarrantsAndSevenYearWarrantsMember
454 Disclosure of financial liabilities [line items] LineItems ifrs-full:DisclosureOfFinancialLiabilitiesLineItems
455 Number of units issued under private placement Concept (Shares) For Period epi:NumberOfUnitsIssuedInPrivatePlacement
456 Amount of gross proceeds of units issued in private placement Concept (Monetary) For Period Debit epi:GrossProceedsFromUnitsIssuedInPrivatePlacement
457 Number of warrants consisted in each unit of private placement Concept (Shares) For Period epi:NumberOfWarrantConsistedInEachUnitOfPrivatePlacement
458 Number of common share consisted in each unit of private placement Concept (Shares) For Period epi:NumberOfCommonShareConsistedInEachUnitOfPrivatePlacement
459 Number of warrants consisted in each unit of private placement Concept (Decimal) For Period epi:NumberOfWarrantsConsistedInEachUnitOfPrivatePlacement
460 Subscription price of units issued in private placement Concept (Per Unit) For Period epi:SubscriptionPriceOfUnitIssuedInPrivatePlacement
461 Exercise price of warrants Concept (Share) For Period epi:ExercisePriceOfWarrants
462 Term of warrants Concept (xbrli:durationItemType) For Period epi:TermOfWarrants
463 Derivative financial liabilities Concept (Monetary) As Of Credit ifrs-full:DerivativeFinancialLiabilities
464 Derivative liability fair value Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilitiesAtFairValue
465 Amount of derivative liability change in fair value Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
466 051 - Disclosure - DERIVATIVE LIABILITIES (Detail Textuals 2) Network

*

*

 http://www.essapharma.com/role/DerivativeLiabilitiesDetailTextuals2
467 Disclosure of financial liabilities [table] Table

*

*

 ifrs-full:DisclosureOfFinancialLiabilitiesTable
468 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
469 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
470 SVB Warrants Member epi:SvbWarrantsMember
471 Arrangement And Non Arrangement Transactions [Axis] Axis epi:ArrangementAndNonArrangementTransactionsAxis
472 Arrangement And Non Arrangement Transactions [Domain] Member epi:ArrangementAndNonArrangementTransactionsDomain
473 Term credit loan facility agreement Member epi:TermCreditLoanFacilityAgreementMember
474 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
475 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
476 Silicon Valley Bank ("SVB") Member epi:SiliconValleyBankMember
477 Disclosure of financial liabilities [line items] LineItems ifrs-full:DisclosureOfFinancialLiabilitiesLineItems
478 Amount of term credit loan Concept (Monetary) As Of Credit ifrs-full:Borrowings
479 Number of warrants granted Concept (Shares) For Period epi:NumberOfWarrantsGranted
480 Exercise price of warrants Concept (Share) For Period epi:ExercisePriceOfWarrants
481 Fair value assigned to warrants issued Concept (Monetary) As Of Credit epi:FairValueOfDerivativeLiability
482 Liquidity discount Concept (Percent) As Of epi:MeasurementInputPercentageOfLiquidityDiscountForLackOfMarketability
483 Derivative liability fair value Concept (Monetary) As Of Credit ifrs-full:FinancialLiabilitiesAtFairValue
484 Amount of derivative liability change in fair value Concept (Monetary) For Period Credit ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
485 052 - Disclosure - DERIVATIVE LIABILITIES (Detail Textuals 3) Network

*

*

 http://www.essapharma.com/role/DerivativeLiabilitiesDetailTextuals3
486 Disclosure of financial liabilities [table] Table

*

*

 ifrs-full:DisclosureOfFinancialLiabilitiesTable
487 Measurement [axis] Axis ifrs-full:MeasurementAxis
488 Aggregated measurement [member] Member ifrs-full:AggregatedMeasurementMember
489 Recurring fair value measurement Member ifrs-full:RecurringFairValueMeasurementMember
490 Levels of fair value hierarchy [axis] Axis ifrs-full:LevelsOfFairValueHierarchyAxis
491 All levels of fair value hierarchy [member] Member ifrs-full:AllLevelsOfFairValueHierarchyMember
492 Level 3 of fair value hierarchy Member ifrs-full:Level3OfFairValueHierarchyMember
493 Disclosure of financial liabilities [line items] LineItems ifrs-full:DisclosureOfFinancialLiabilitiesLineItems
494 Sensitivity analysis of fair value, increase in derivative warrants, impact of 10 percent increase in market price Concept (Monetary) As Of Credit epi:SensitivityAnalysisOfFairValueIncreaseInDerivativeWarrantsImpactOfTenPercentIncreaseInMarketPrice
495 Sensitivity analysis of fair value, Decrease in derivative warrants, impact of 10 percent Decrease in market price Concept (Monetary) As Of Credit epi:SensitivityAnalysisOfFairValueDecreaseInDerivativeWarrantsImpactOfTenPercentDecreaseInMarketPrice
496 Sensitivity analysis of fair value, increase in derivative warrants, impact of 10 percent increase in volatility Concept (Monetary) As Of Credit epi:SensitivityAnalysisOfFairValueIncreaseInDerivativeWarrantsImpactOfTenPercentIncreaseInVolatility
497 Sensitivity analysis of fair value, Decrease in derivative warrants, impact of 10 percent Decrease in volatility Concept (Monetary) As Of Credit epi:SensitivityAnalysisOfFairValueDecreaseInDerivativeWarrantsImpactOfTenPercentDecreaseInVolatility
498 053 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIENCY) (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/ShareholdersEquityDeficiencyDetailTextuals
499 Disclosure of classes of share capital [table] Table

*

*

 ifrs-full:DisclosureOfClassesOfShareCapitalTable
500 Classes of financial liabilities [axis] Axis ifrs-full:ClassesOfFinancialLiabilitiesAxis
501 Financial liabilities, class [member] Member ifrs-full:FinancialLiabilitiesMember
502 Special broker warrants Member epi:SpecialBrokerWarrantsMember
503 Borker Warrant Member epi:BorkerWarrantMember
504 Broker Warrants Member epi:BrokerWarrantsMember
505 Pre-funded warrants Member epi:PreFundedWarrantsMember
506 Classes of share capital [axis] Axis ifrs-full:ClassesOfShareCapitalAxis
507 Share capital [member] Member ifrs-full:ClassesOfShareCapitalMember
508 Preferred shares Member ifrs-full:PreferenceSharesMember
509 January 2018 Financing Member epi:JanuaryFinancing2018Member
510 March 2016 Private Placement Member epi:PrivatePlacementMarch2016Member
511 January 2016 Private Placement Member epi:PrivatePlacementJanuary2016Member
512 January 2015 Special Warrant Financing Member epi:SpecialWarrantFinancingJanuary2015Member
513 October 2014 Special Warrant Financing Member epi:SpecialWarrantFinancingOctober2014Member
514 Business combinations [axis] Axis ifrs-full:BusinessCombinationsAxis
515 Entity's total for business combinations [member] Member ifrs-full:EntitysTotalForBusinessCombinationsMember
516 Clarus Lifesciences III, L.P. ("Clarus") Member epi:ClarusLifesciencesIiiMember
517 Omega Fund IV, L.P. (Omega) Member epi:OmegaFundIvLpMember
518 Arrangement And Non Arrangement Transactions [Axis] Axis epi:ArrangementAndNonArrangementTransactionsAxis
519 Arrangement And Non Arrangement Transactions [Domain] Member epi:ArrangementAndNonArrangementTransactionsDomain
520 Voting agreement Member epi:VotingAgreementMember
521 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
522 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
523 Bloom Burton & Co Member epi:BloomBurtonCoMember
524 Roth Capital Partners, LLC Member epi:RothCapitalPartnersLlcMember
525 Bloom Burton & Co. And Roth Capital Partners, Llc Member epi:BloomBurtonCo.AndRothCapitalPartnersLlcMember
526 Counterparties [axis] Axis ifrs-full:CounterpartiesAxis
527 Counterparties [member] Member ifrs-full:CounterpartiesMember
528 Agent Member epi:AgentMember
529 Finder Member epi:FinderMember
530 Tranche [Axis] Axis epi:TrancheAxis
531 Tranche [Domain] Member epi:TrancheDomain
532 First Tranche Member epi:FirstTrancheMember
533 Second Tranche Member epi:SecondTrancheMember
534 Disclosure of classes of share capital [line items] LineItems ifrs-full:DisclosureOfClassesOfShareCapitalLineItems
535 Fair value of warrants issued Concept (Monetary) As Of Credit epi:FairValueOfWarrantsIssued
536 Exercise price per broker warrant Concept (Share) As Of epi:ExercisePricePerBrokerWarrant
537 Number of warrants issued Concept (Shares) For Period epi:NumberOfWarrantIssued
538 Number of warrants acquired Concept (Shares) For Period epi:NumberOfWarrantsAcquired
539 Term of warrants Concept (xbrli:durationItemType) For Period epi:TermOfWarrantsIssued
540 Expected life Concept (xbrli:durationItemType) For Period epi:WarrantLifeWarrantsIssued
541 Risk-free interest rate Concept (Percent) For Period epi:RiskFreeInterestRateWarrantsIssued
542 Derivative volatility rate Concept (Percent) For Period ifrs-full:HistoricalVolatilityForSharesSignificantUnobservableInputsLiabilities
543 Volatility rate Concept (Percent) For Period epi:VolatilityRate
544 Dividend rate Concept (Percent) For Period epi:ExpectedDividendAsPercentageWarrants
545 Conversion of preferred shares (in shares) Concept (Shares) For Period epi:ConversionOfPreferredStockShares
546 Number of shares issued Concept (Shares) As Of ifrs-full:NumberOfSharesIssued
547 Number of shares outstanding Concept (Shares) As Of ifrs-full:NumberOfSharesOutstanding
548 Minimum bid price of NASDAQ compliance for listing requirements Concept (Share) For Period epi:MinimumBidPriceOfStockExchangeComplianceForListingRequirements
549 Minimum market value of NASDAQ compliance for listing requirements Concept (Monetary) For Period Debit epi:MinimumMarketValueOfStockExchangeComplianceForListingRequirements
550 Noncompliance constituting continued deficiency for consecutive business days of NASDAQ compliance for listing requirements Concept (xbrli:durationItemType) For Period epi:NoncomplianceConstitutingContinuedDeficiencyForConsecutiveBusinessDaysOfStockExchangeComplianceForListingRequirements
551 Grace period for regain compliance requirements Concept (xbrli:durationItemType) For Period epi:GracePeriodForRegainComplianceRequirements
552 Number of shares issued for financing Concept (Shares) For Period epi:NumberOfSharesIssuedForFinancing
553 Number of units issued for private placement Concept (Shares) For Period epi:NumberOfUnitsIssuedForPrivatePlacement
554 Proceeds from issuing shares Concept (Monetary) For Period Debit ifrs-full:ProceedsFromIssuingShares
555 Gross proceeds on issuance of common shares and warrants Concept (Monetary) For Period Debit epi:GrossProceedsOnIssuanceOfCommonSharesAndWarrants
556 Gross proceeds on issuance of units Concept (Monetary) For Period Debit epi:GrossProceedsOnIssuanceOfUnits
557 Subscription price per common share Concept (Share) As Of epi:SubscriptionPricePerShare
558 Exercise price for warrants Concept (Share) As Of epi:ExercisePriceForWarrants
559 Subscription price for pre-funded warrants Concept (Share) As Of epi:SubscriptionPriceOfPreFundedWarrants
560 Subscription price per unit Concept (Per Unit) As Of epi:SubscriptionPricePerUnit
561 Par value per share Concept (Share) As Of ifrs-full:ParValuePerShare
562 Deferred financing costs Concept (Monetary) For Period Debit epi:DeferredFinancingCost
563 Financing costs Concept (Monetary) For Period Debit epi:FinancingCosts
564 Finance costs for issuance of warrants Concept (Monetary) For Period Debit epi:FinanceCostsForIssuanceOfWarrants
565 Amount of other financing costs Concept (Monetary) For Period Debit epi:OtherFinancingCosts
566 Finance expense for share issuance Concept (Monetary) For Period Credit epi:FinanceExpense
567 Amount of cash commission to agent Concept (Monetary) For Period Debit ifrs-full:FeeAndCommissionExpense
568 Number of common shares acquired Concept (Shares) For Period epi:NumberOfCommonSharesAcquired
569 Number of common shares controlled by shareholders under voting agreement Concept (Shares) For Period epi:NumberOfCommonSharesControlledByShareholdersUnderVotingAgreement
570 Ownership threshold of common shares to be held by Omega to maintain nomination rights Concept (Percent) As Of epi:OwnershipThresholdOfCommonSharesToBeHeldByOmegaToMaintainNominationRights
571 Ownership by shareholders under voting agreement Concept (Percent) As Of epi:OwnershipByShareholdersUnderVotingAgreement
572 Minimum number of common shares to be held by Clarus to maintain nomination rights Concept (Shares) For Period epi:MinimumNumberOfCommonSharesHeldByEntity
573 Fair value of warrants Concept (Monetary) As Of Credit epi:FairValueOfWarrants
574 Derivative financial liabilities Concept (Monetary) As Of Credit ifrs-full:DerivativeFinancialLiabilities
575 Agent and finders' fees on special warrant financing Concept (Monetary) For Period Debit epi:AgentAndFindersFeesOnSpecialWarrantFinancing
576 Rate of fees paid on funds raised by agent and finders Concept (Percent) For Period epi:RateOfFeesPaidOnFundsRaisedByAgentAndFinders
577 Rate of compensation in Special Broker Warrants Concept (Percent) For Period epi:RateOfCompensationInSpecialBrokerWarrants
578 Number of additional common shares issued for which partial exercised over-allotment option Concept (Shares) For Period epi:NumberOfAdditionalCommonSharesIssuedForWhichPartialExercisedOver-AllotmentOption
579 Additional proceeds of common shares issued for which partial exercised over-allotment option Concept (Monetary) For Period Debit epi:AdditionalProceedsOfCommonSharesIssuedForWhichPartialExercisedOver-AllotmentOption
580 Number of common share into which each warrant exercisable Concept (Shares) For Period epi:NumberOfCommonShareIntoWhichEachWarrantExercisable
581 Reverse stock split, conversion ratio Concept (Pure) For Period epi:ReverseStockSplitConversionRatio
582 054 - Disclosure - RESERVES (Details) Network

*

*

 http://www.essapharma.com/role/RESERVESDetails
583 Implied Table Table

*

*

 implied:Table
584 Disclosure of reserves within equity [abstract] Abstract ifrs-full:DisclosureOfReservesWithinEquityAbstract
585 Number of Options Abstract epi:NumberOfShareOptionsAbstract
586 Balance outstanding, beginning Concept (Decimal) As Of ifrs-full:NumberOfOutstandingShareOptions
587 Options granted Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
588 Options exercised Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
589 Options expired/forfeited Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement
590 Balance outstanding, ending Concept (Decimal) As Of ifrs-full:NumberOfOutstandingShareOptions
591 Balance exercisable Concept (Decimal) As Of ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
592 Weighted Average Exercise Price Abstract epi:WeightedAverageExercisePriceAbstract
593 Balance outstanding, beginning Concept (Monetary) As Of ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement
594 Options granted Concept (Monetary) For Period ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement
595 Options exercised Concept (Monetary) For Period ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement
596 Options expired/forfeited Concept (Monetary) For Period ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement
597 Balance outstanding, ending Concept (Monetary) As Of ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement
598 Balance exercisable Concept (Monetary) As Of ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement
599 055 - Disclosure - RESERVES (Details 1) Network

*

*

 http://www.essapharma.com/role/RESERVESDetails1
600 Disclosure of number and weighted average remaining contractual life of outstanding share options [table] Table

*

*

 ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable
601 Ranges of exercise prices for outstanding share options [axis] Axis ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis
602 Ranges of exercise prices for outstanding share options [member] Member ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsMember
603 $4.00 Member epi:RangesOfExercisePricesForOutstandingShareOptions4.00Member
604 $4.10 Member epi:RangesOfExercisePricesForOutstandingShareOptions4.10Member
605 C$4.90 Member epi:RangesOfExercisePricesForOutstandingShareOptions4.90Member
606 C$16.00 Member epi:RangesOfExercisePricesForOutstandingShareOptions16.00Member
607 C$40.00 Member epi:RangesOfExercisePricesForOutstandingShareOptions40.00Member
608 Disclosure of number and weighted average remaining contractual life of outstanding share options [line items] LineItems ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems
609 Exercise price Concept (Monetary) As Of ifrs-full:ExercisePriceOfOutstandingShareOptions
610 Number of options Concept (Decimal) As Of ifrs-full:NumberOfOutstandingShareOptions
611 Weighted average remaining contractual life (years) Concept (Decimal) As Of ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions
612 056 - Disclosure - RESERVES (Details 2) Network

*

*

 http://www.essapharma.com/role/RESERVESDetails2
613 Disclosure of terms and conditions of share-based payment arrangement [table] Table

*

*

 ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
614 Income Statement Locations Axis Axis epi:IncomeStatementLocationsAxis
615 Income Statement Locations Domain Member epi:IncomeStatementLocationsDomain
616 Research and development expense (Note 18) Member epi:ResearchAndDevelopmentExpensesMember
617 Financing costs Member epi:FinancingCostsMember
618 General and administrative (Note 18) Member epi:GeneralAndAdministrativeMember
619 Disclosure of terms and conditions of share-based payment arrangement [line items] LineItems ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
620 Share-based payments expense Concept (Monetary) For Period Debit ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
621 057 - Disclosure - RESERVES (Details 3) Network

*

*

 http://www.essapharma.com/role/RESERVESDetails3
622 Implied Table Table

*

*

 implied:Table
623 Disclosure of reserves within equity [abstract] Abstract ifrs-full:DisclosureOfReservesWithinEquityAbstract
624 Risk-free interest rate Concept (Percent) For Period ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
625 Expected life of options (years) Concept (Decimal) For Period ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
626 Expected annualized volatility Concept (Percent) For Period ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
627 Dividend Concept (Percent) For Period ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
628 058 - Disclosure - RESERVES (Details 4) Network

*

*

 http://www.essapharma.com/role/RESERVESDetails4
629 Implied Table Table

*

*

 implied:Table
630 Disclosure of reserves within equity [abstract] Abstract ifrs-full:DisclosureOfReservesWithinEquityAbstract
631 Number of Warrants Abstract epi:NumberOfOtherEquityInstrumentsAbstract
632 Balance outstanding, beginning Concept (Decimal) As Of ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
633 Warrants granted Concept (Decimal) For Period ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
634 Warrants exercised Concept (Decimal) For Period ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
635 Warrants expired Concept (Decimal) For Period epi:NumberOfInstrumentsOtherEquityInstrumentsExpired
636 Balance outstanding, ending Concept (Decimal) As Of ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
637 Balance exercisable Concept (Decimal) As Of ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
638 Weighted Average Exercise Price Abstract epi:WeightedAverageExercisePriceOfOtherEquityInstrumentsAbstract
639 Balance outstanding, beginning Concept (Monetary) As Of ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
640 Warrants granted Concept (Monetary) For Period ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement
641 Warrants exercised Concept (Monetary) For Period ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
642 Warrants expired Concept (Monetary) For Period epi:WeightedAverageExercisePriceOfOtherEquityInstrumentsCancelledOrExpiredInShareBasedPaymentArrangement
643 Balance outstanding, ending Concept (Monetary) As Of ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
644 Balance exercisable Concept (Monetary) As Of ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
645 059 - Disclosure - RESERVES (Details 5) Network

*

*

 http://www.essapharma.com/role/RESERVESDetails5
646 Disclosure Of Number Warrants Exercise Price And Expiry Date [Table] Table

*

*

 epi:DisclosureOfNumberWarrantsExercisePriceAndExpiryDateTable
647 Ranges Of Exercise Prices For Equity Instruments [Axis] Axis epi:RangesOfExercisePricesForEquityInstrumentsAxis
648 Ranges Of Exercise Prices For Equity Instruments [Domain] Member epi:RangesOfExercisePricesForEquityInstrumentsDomain
649 C$40.00 Member epi:RangesOfExercisePricesForEquityInstruments40.00Member
650 US$66.00 Member epi:RangesOfExercisePricesForEquityInstruments66.00Member
651 US$42.80 Member epi:RangesOfExercisePricesForEquityInstruments42.80Member
652 US$0.002 Member epi:RangesOfExercisePricesForEquityInstruments0.002Member
653 US$4.00 Member epi:RangesOfExercisePricesForEquityInstruments4.00Member
654 Expiry Date [Axis] Axis epi:ExpiryDateAxis
655 Expiry Date [Domain] Member epi:ExpiryDateDomain
656 April 15, 2019 Member epi:ExpirationDateFifteenAprilTwoThousandNineteenMember
657 January 14, 2023 Member epi:ExpirationDateJanuaryFourteenTwoThousandTwentyThreeMember
658 November 18, 2023 Member epi:ExpirationDateNovemberEighteenTwoThousandTwentyThreeMember
659 January 9, 2023 Member epi:ExpirationDateJanuaryNineTwoThousandTwentyThreeMember
660 January 16, 2023 Member epi:ExpirationDateJanuarySixteenTwoThousandTwentyThreeMember
661 Disclosure Of Number Warrants Exercise Price And Expiry Date [Line Items] LineItems epi:DisclosureOfNumberWarrantsExercisePriceAndExpiryDateLineItems
662 Number of Warrants Concept (Decimal) As Of ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
663 Exercise Price Concept (Monetary) As Of ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
664 060 - Disclosure - RESERVES (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/RESERVESDetails6
665 Disclosure of defined benefit plans [table] Table

*

*

 ifrs-full:DisclosureOfDefinedBenefitPlansTable
666 Defined benefit plans [axis] Axis ifrs-full:DefinedBenefitPlansAxis
667 Defined benefit plans [member] Member ifrs-full:DefinedBenefitPlansMember
668 Stock Option Plan And RSU Plan Member epi:StockOptionPlanAndRsuPlanMember
669 Disclosure of defined benefit plans [line items] LineItems ifrs-full:DisclosureOfDefinedBenefitPlansLineItems
670 Number of common shares reserved for issuance Concept (Shares) As Of ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
671 Stock options term Concept (xbrli:durationItemType) For Period epi:TermsOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
672 061 - Disclosure - RESERVES (Detail Textuals 1) Network

*

*

 http://www.essapharma.com/role/ReservesDetailTextuals1
673 Implied Table Table

*

*

 implied:Table
674 Disclosure of reserves within equity [abstract] Abstract ifrs-full:DisclosureOfReservesWithinEquityAbstract
675 Number of share options granted in share-based payment arrangement Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
676 Weighted average fair value of option pricing Concept (Share) For Period epi:ShareBasedCompensationArrangementByShare-BasedPaymentAwardOptionGrantsInPeriodWeightedAverageGrantDateFairValue
677 062 - Disclosure - RESERVES (Detail Textuals 2) Network

*

*

 http://www.essapharma.com/role/ReservesDetailTextuals2
678 Disclosure of terms and conditions of share-based payment arrangement [table] Table

*

*

 ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable
679 Types of share-based payment arrangements [axis] Axis ifrs-full:TypesOfSharebasedPaymentArrangementsAxis
680 Share-based payment arrangements [member] Member ifrs-full:SharebasedPaymentArrangementsMember
681 Amended share-based compensation Member epi:AmendedShare-BasedCompensationMember
682 Range [axis] Axis ifrs-full:RangeAxis
683 Ranges [member] Member ifrs-full:RangesMember
684 Minimum Member ifrs-full:BottomOfRangeMember
685 Maximum Member ifrs-full:TopOfRangeMember
686 Disclosure of terms and conditions of share-based payment arrangement [line items] LineItems ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems
687 Number of options Concept (Decimal) As Of ifrs-full:NumberOfOutstandingShareOptions
688 Exercise price of outstanding share options Concept (Monetary) As Of ifrs-full:ExercisePriceOfOutstandingShareOptions
689 Share-based payments expense Concept (Monetary) For Period Debit ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
690 Expected volatility, share options granted Concept (Percent) For Period ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
691 Risk free interest rate, share options granted Concept (Percent) For Period ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
692 Expected life of options (years) Concept (Decimal) For Period ifrs-full:DescriptionOfOptionLifeShareOptionsGranted
693 Expected dividend as percentage, share options granted Concept (Percent) For Period ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
694 Expiry date of outstanding stock options Concept (Text/String) For Period epi:ExpiryDateOfOutstandingStockOptions
695 Subscription price per common share Concept (Share) As Of epi:SubscriptionPricePerShare
696 063 - Disclosure - SUPPLEMENTAL DISCLOSURE WITH RESPECT TO CASH FLOWS (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/SupplementalDisclosureWithRespectToCashFlowsDetailTextuals
697 Implied Table Table

*

*

 implied:Table
698 Supplemental Disclosure Of Cash Flow Statement [Abstract] Abstract epi:SupplementalDisclosureOfCashFlowStatementAbstract
699 Value for issuing broker warrant Concept (Monetary) For Period Credit epi:ValueForIssuingBrokerWarrant
700 Derivative liability recognized Concept (Monetary) For Period Credit epi:DerivativeLiabilityOnIssuanceOfWarrants
701 Reserves transferred to share capital on exercise of stock options Concept (Monetary) As Of Credit epi:ReservesTransferredToShareCapitalOnExerciseOfStockOptions
702 Number of stock issued as result of cashless exercise of stock options (in shares) Concept (Shares) For Period epi:NumberOfStockIssuedAsResultOfCashlessExerciseOfStockOptions
703 Number of stock options exercised (in shares) Concept (Shares) For Period epi:NumberOfStockOptionsExercised
704 Reserves transferred to share capital on exercise of warrants Concept (Monetary) As Of epi:ReservesTransferredToShareCapitalOnExerciseOfWarrants
705 064 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Network

*

*

 http://www.essapharma.com/role/RELATEDPARTYTRANSACTIONSDetails
706 Implied Table Table

*

*

 implied:Table
707 Related party transactions [abstract] Abstract ifrs-full:RelatedPartyTransactionsAbstract
708 Salaries, consulting fees, and director fees Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
709 Share-based payments, net of cancellations Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
710 Total compensation Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensation
711 065 - Disclosure - RELATED PARTY TRANSACTIONS (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/RelatedPartyTransactionsDetailsTextuals
712 Disclosure of transactions between related parties [table] Table

*

*

 ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesTable
713 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
714 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
715 Key management personnel Member ifrs-full:KeyManagementPersonnelOfEntityOrParentMember
716 CEO Member epi:ChiefExecutiveOfficersMember
717 CFO Member epi:ChiefFinancialOfficersMember
718 COO Member epi:ChiefOperatingOfficersMember
719 Disclosure of transactions between related parties [line items] LineItems ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesLineItems
720 Number of stock options modified Concept (Decimal) For Period epi:NumberOfShareOptionsModifiedInShareBasedPaymentArrangement
721 Number of stock options granted Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
722 Share-based payments expense Concept (Monetary) For Period Debit ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
723 Amounts payable, related party transactions Concept (Monetary) As Of Credit ifrs-full:AmountsPayableRelatedPartyTransactions
724 Period of base salary paid upon termination without cause Concept (xbrli:durationItemType) For Period epi:PeriodOfBaseSalaryPaidUponTerminationWithoutCause
725 Period of salary entitled if termination without cause occurs after or within 60 days prior to change of control event Concept (xbrli:durationItemType) For Period epi:PeriodOfSalaryEntitledIfTerminationWithoutCauseOccursAfterOrWithin60DaysPriorToChangeOfControlEvent
726 Period of salary entitled if termination without cause occurs within 18 months after a change of control event Concept (xbrli:durationItemType) For Period epi:PeriodOfSalaryEntitledIfTerminationWithoutCauseOccursWithin18MonthsAfterChangeOfControlEvent
727 066 - Disclosure - INCOME TAXES (Details) Network

*

*

 http://www.essapharma.com/role/INCOMETAXESDetails
728 Implied Table Table

*

*

 implied:Table
729 Income Taxes [Abstract] Abstract epi:IncomeTaxesAbstract
730 Loss for the year before income tax Concept (Monetary) For Period Credit ifrs-full:ProfitLossBeforeTax
731 Expected income tax recovery Concept (Monetary) For Period Debit ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
732 Non-deductible share-based payments Concept (Monetary) For Period Debit epi:ReconciliationOfNonDeductibleShareBasedPayments
733 Other permanent differences including foreign exchange Concept (Monetary) For Period Debit epi:ReconciliationOfOtherPermanentDifferencesIncludingForeignExchange
734 Financing costs Concept (Monetary) For Period Debit ifrs-full:TaxEffectOfTaxLosses
735 Changes in statutory and foreign tax rates and other Concept (Monetary) For Period Debit ifrs-full:TaxEffectOfForeignTaxRates
736 Adjustment to prior year provision versus statutory return Concept (Monetary) For Period Debit ifrs-full:TaxEffectFromChangeInTaxRate
737 Change in unrecognized deductible temporary differences Concept (Monetary) For Period Debit epi:TaxEffectOfChangeInUnrecognizedOfTemporaryDifference
738 Total income tax expense Concept (Monetary) For Period Debit ifrs-full:IncomeTaxExpenseContinuingOperations
739 067 - Disclosure - INCOME TAXES (Details 1) Network

*

*

 http://www.essapharma.com/role/INCOMETAXESDetails1
740 Implied Table Table

*

*

 implied:Table
741 Income Taxes [Abstract] Abstract epi:IncomeTaxesAbstract
742 Operating losses carried forward Concept (Monetary) As Of Debit epi:ComponentsOfOperatingLossesCarriedForward
743 Investment tax credits Concept (Monetary) As Of Debit epi:ComponentsOfInvestmentTaxCredits
744 Equipment and intangible assets Concept (Monetary) As Of Debit epi:ComponentsOfEquipmentAndIntangibleAssets
745 Financing costs Concept (Monetary) As Of Credit epi:ComponentsOfFinancingCosts
746 068 - Disclosure - INCOME TAXES (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/IncomeTaxesDetailsTextuals
747 Implied Table Table

*

*

 implied:Table
748 Income Taxes [Abstract] Abstract epi:IncomeTaxesAbstract
749 Operating losses carried forward expiration period Concept (Text/String) For Period epi:OperatingLossesCarriedForwardExpirationPeriod
750 Financing costs expiration period Concept (Text/String) For Period epi:FinancingCostsExpirationPeriod
751 Investment tax credits expiration period Concept (Text/String) For Period epi:InvestmentTaxCreditsExpirationPeriod
752 Income tax expense Concept (Monetary) For Period Debit ifrs-full:IncomeTaxExpenseContinuingOperations
753 Federal corporate income tax rate Concept (Percent) For Period ifrs-full:ApplicableTaxRate
754 Federal and Provincial (BC) general corporate income tax rate Concept (Percent) For Period epi:FederalAndProvincialGeneralCorporateIncomeTaxRate
755 General corporate income tax rate Concept (Percent) For Period epi:GeneralCorporateIncomeTaxRate
756 069 - Disclosure - CAPITAL MANAGEMENT (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/CapitalManagementDetailTextuals
757 Disclosure of detailed information about borrowings [table] Table

*

*

 ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsTable
758 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
759 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
760 SVB Term Loan Member epi:SvbTermLoanMember
761 Disclosure of detailed information about borrowings [line items] LineItems ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsLineItems
762 Term loan Concept (Monetary) For Period Debit epi:LoanAdvance
763 070 - Disclosure - FINANCIAL INSTRUMENTS AND RISK (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/FinancialInstrumentsAndRiskDetailsTextuals
764 Disclosure of detailed information about financial instruments [table] Table

*

*

 ifrs-full:DisclosureOfFinancialInstrumentsTable
765 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
766 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
767 SVB Term Loan Member epi:SvbTermLoanMember
768 Arrangement And Non Arrangement Transactions [Axis] Axis epi:ArrangementAndNonArrangementTransactionsAxis
769 Arrangement And Non Arrangement Transactions [Domain] Member epi:ArrangementAndNonArrangementTransactionsDomain
770 Term credit loan facility agreement Member epi:TermCreditLoanFacilityAgreementsMember
771 Tranche [Axis] Axis epi:TrancheAxis
772 Tranche [Domain] Member epi:TrancheDomain
773 Third and final tranche Member epi:ThirdAndFinalTrancheMember
774 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
775 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
776 Cancer Prevention Research Institute of Texas (CPRIT) Member epi:CancerPreventionResearchInstituteOfTexasMember
777 Types of risks [axis] Axis ifrs-full:TypesOfRisksAxis
778 Risks [member] Member ifrs-full:TypesOfRisksMember
779 Interest rate risk Member ifrs-full:InterestRateRiskMember
780 Foreign currency risk Member ifrs-full:CurrencyRiskMember
781 Disclosure of detailed information about financial instruments [line items] LineItems ifrs-full:DisclosureOfFinancialInstrumentsLineItems
782 Fair value of principal and financing costs Concept (Monetary) As Of Credit epi:FairValueOfPrincipalAndFinancingCosts
783 Working Capital Concept (Monetary) As Of Credit epi:WorkingCapital
784 Period of SVB term loan Concept (xbrli:durationItemType) For Period epi:TermOfDebtInstrument
785 Long term debt maturity Concept (Date) For Period epi:LongTermDebtMaturity
786 Impact of 10% change in WSJ Prime Rate result increase in realized net loss Concept (Monetary) For Period Debit epi:SensitivityAnalysisImpactOf10PercentChangeInInterestRateIncreaseInRealizedNetLoss
787 Impact of 10% change in WSJ Prime Rate result decrease in realized net loss Concept (Monetary) For Period Debit epi:SensitivityAnalysisImpactOf10PercentChangeInInterestRateDecreaseInRealizedNetLoss
788 Impact of 10% change in foreign exchange rate between CAD and USD, Fluctuation in realized net loss Concept (Monetary) For Period Debit epi:SensitivityAnalysisImpactOf10PercentChangeInForeignExchangeRateBetweenCadAndUsdFluctuationInRealizedNetLoss
789 071 - Disclosure - COMMITMENTS (Details) Network

*

*

 http://www.essapharma.com/role/CommitmentsDetails
790 Contractual Obligations [Table] Table

*

*

 epi:ContractualObligationsTable
791 Arrangements And Non-Arrangement Transactions [Axis] Axis epi:ArrangementsAndNon-ArrangementTransactionsAxis
792 Type Of Arrangement [Member] Member epi:TypeOfArrangementMember
793 Minimum Contractual obligations Member epi:LicenseAgreementMember
794 Collaborative Research Agreement with BC Cancer Agency Member epi:CollaborativeResearchAgreementMember
795 Maturity [axis] Axis ifrs-full:MaturityAxis
796 Aggregated time bands [member] Member ifrs-full:AggregatedTimeBandsMember
797 2019 Member ifrs-full:NotLaterThanOneYearMember
798 2020 Member ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember
799 2021 Member ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember
800 2022 Member ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember
801 2023 Member ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember
802 Contractual Obligations [Line Items] LineItems epi:ContractualObligationsLineItems
803 Minimum annual royalty per License Agreement (Note 6) Concept (Monetary) For Period Credit epi:MinimumAdvanceRoyaltyPayments
804 Collaborative Research Agreement with BC Cancer Agency Concept (Monetary) For Period Credit epi:PaymentsForContractualObligations
805 Total (in C$) Concept (Monetary) For Period Credit epi:MinimumAnnualRoyaltyAndPaymentsForContractualObligations
806 SVB loan payments (Note 7) Concept (Monetary) For Period Debit epi:ObligationsForLoanPayments
807 Lease on US office spaces Concept (Monetary) For Period Debit epi:LeaseOnOfficeSpaces
808 072 - Disclosure - COMMITMENTS (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/CommitmentsDetailTextuals
809 Contractual Obligations [Table] Table

*

*

 epi:ContractualObligationsTable
810 Categories of related parties [axis] Axis ifrs-full:CategoriesOfRelatedPartiesAxis
811 Entity's total for related parties [member] Member ifrs-full:EntitysTotalForRelatedPartiesMember
812 Cancer Prevention Research Institute of Texas (CPRIT) Member epi:CancerPreventionResearchInstituteOfTexasMember
813 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
814 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
815 Cprit Grant After Reporting Period Member ifrs-full:MajorBusinessCombinationMember
816 Tranche [Axis] Axis epi:TrancheAxis
817 Tranche [Domain] Member epi:TrancheDomain
818 First two tranches Member epi:FirstTwoTranchesMember
819 Third and final tranche Member epi:ThirdAndFinalTrancheMember
820 Borrowings by name [axis] Axis ifrs-full:BorrowingsByNameAxis
821 Borrowings by name [member] Member ifrs-full:BorrowingsByNameMember
822 Term credit loan facility agreement Member epi:TermCreditLoanFacilityAgreementMember
823 Contractual Obligations [Line Items] LineItems epi:ContractualObligationsLineItems
824 Maximum eligibility for product development and relocation grant Concept (Monetary) For Period Credit epi:MaximumEligibilityForProductDevelopmentAndRelocationGrant
825 Eligibility period for product development and relocation grant Concept (xbrli:durationItemType) For Period epi:EligibilityPeriodForProductDevelopmentAndRelocationGrant
826 Percentage of funding raise to release CPRIT monies Concept (Percent) For Period epi:PercentageOfFundingRaiseToReleaseCpritMonies
827 Product development and relocation grant Concept (Monetary) For Period Credit ifrs-full:RevenueFromGovernmentGrants
828 Third tranche of product development and relocation grant Concept (Monetary) For Period Credit epi:ThirdTrancheOfProductDevelopmentAndRelocationGrant
829 Remaining balance expected to be received after completion of grant term Concept (Monetary) For Period Credit epi:RemainingBalanceExpectedToBeReceivedAfterCompletionOfGrantTerm
830 Threshold limit for aggregate royalty payments Concept (Monetary) For Period Debit epi:ThresholdLimitForAggregateRoyaltyPayments
831 Royalty rate on revenues for CPRIT royalty under threshold Concept (Percent) For Period epi:PercentageOfRevenuesUntilAggregateRoyaltyPaymentsEqualThreshold
832 Royalty rate on revenues for CPRIT royalty after threshold Concept (Percent) For Period epi:PercentageOfRevenuesThereafter
833 073 - Disclosure - EXPENSES BY NATURE (Details) Network

*

*

 http://www.essapharma.com/role/EXPENSESBYNATUREDetails
834 Expense By Nature [Table] Table

*

*

 epi:ExpenseByNatureTable
835 Income Statement Locations Axis Axis epi:IncomeStatementLocationsAxis
836 Income Statement Locations Domain Member epi:IncomeStatementLocationsDomain
837 Research and development expense Member epi:ResearchAndDevelopmentExpensesMember
838 Expense By Nature [Line Items] LineItems epi:ExpenseByNatureLineItems
839 Clinical Concept (Monetary) For Period Debit epi:ResearchAndDevelopmentExpenseAllocationClinical
840 Consulting Concept (Monetary) For Period Debit epi:ConsultingFee
841 Legal patents and license fees Concept (Monetary) For Period Debit epi:ResearchAndDevelopmentExpenseAllocationLegalPatentsAndLicenseFees
842 Manufacturing Concept (Monetary) For Period Debit epi:ResearchAndDevelopmentExpenseAllocationManufacturingExpense
843 Other Concept (Monetary) For Period Debit ifrs-full:OtherExpenseByNature
844 Pharmacology Concept (Monetary) For Period Debit epi:ResearchAndDevelopmentExpenseAllocationPharmacologyExpense
845 Preclinical Concept (Monetary) For Period Debit epi:ResearchAndDevelopmentExpenseAllocationPreclinicalExpense
846 Program administration Concept (Monetary) For Period Debit epi:ResearchAndDevelopmentExpenseAllocationProgramAdministrationExpense
847 Royalties Concept (Monetary) For Period Debit ifrs-full:RoyaltyExpense
848 Salaries and benefits Concept (Monetary) For Period Debit ifrs-full:WagesAndSalaries
849 Share-based payments (Note 10) Concept (Monetary) For Period Debit ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
850 Travel Concept (Monetary) For Period Debit ifrs-full:TravelExpense
851 CPRIT grant claimed on eligible expenses (Note 17) Concept (Monetary) For Period Credit ifrs-full:RevenueFromGovernmentGrants
852 Total Concept (Monetary) For Period Debit ifrs-full:ResearchAndDevelopmentExpense
853 074 - Disclosure - EXPENSES BY NATURE (Details 1) Network

*

*

 http://www.essapharma.com/role/EXPENSESBYNATUREDetails1
854 Expense By Nature [Table] Table

*

*

 epi:ExpenseByNatureTable
855 Income Statement Locations Axis Axis epi:IncomeStatementLocationsAxis
856 Income Statement Locations Domain Member epi:IncomeStatementLocationsDomain
857 General and administrative expenses Member epi:GeneralAndAdministrativeMember
858 Expense By Nature [Line Items] LineItems epi:ExpenseByNatureLineItems
859 Amortization Concept (Monetary) For Period Debit epi:AmortizationExpenseOfTangibleAndIntangibleAssets
860 Consulting and subcontractor fees Concept (Monetary) For Period Debit epi:GeneralAndAdministrativeExpenseAllocationConsultingAndSubcontractorFeesExpense
861 Director fees Concept (Monetary) For Period Debit epi:GeneralAndAdministrativeExpenseAllocationDirectorFeesExpense
862 Insurance Concept (Monetary) For Period Debit ifrs-full:InsuranceExpense
863 Investor relations Concept (Monetary) For Period Debit epi:GeneralAndAdministrativeExpenseAllocationInvestorRelationsExpense
864 Office, IT and communications Concept (Monetary) For Period Debit epi:GeneralAndAdministrativeExpenseAllocationOfficeItAndCommunications
865 Professional fees Concept (Monetary) For Period Debit ifrs-full:ProfessionalFeesExpense
866 Regulatory fees and transfer agent Concept (Monetary) For Period Debit epi:GeneralAndAdministrativeExpenseAllocationRegulatoryFeesAndTransferAgent
867 Rent Concept (Monetary) For Period Debit epi:GeneralAndAdministrativeExpenseAllocationRentExpense
868 Salaries and benefits Concept (Monetary) For Period Debit ifrs-full:WagesAndSalaries
869 Share-based payments (Note 10) Concept (Monetary) For Period Debit ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
870 Travel and entertainment Concept (Monetary) For Period Debit ifrs-full:TravelExpense
871 Total Concept (Monetary) For Period Debit ifrs-full:GeneralAndAdministrativeExpense
872 075 - Disclosure - SUBSEQUENT EVENTS (Detail Textuals) Network

*

*

 http://www.essapharma.com/role/SubsequentEventsDetailTextuals
873 Disclosure of non-adjusting events after reporting period [table] Table

*

*

 ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodTable
874 Non-adjusting events after reporting period [axis] Axis ifrs-full:NonadjustingEventsAfterReportingPeriodAxis
875 Non-adjusting events after reporting period [member] Member ifrs-full:NonadjustingEventsMember
876 Pre funded warrants stock option after reporting date Member epi:PreFundedWarrantsStockOptionAfterReportingDateMember
877 Stock option events after reporting period Member epi:StockOptionEventsAfterReportingPeriodMember
878 Legal Entity Axis Axis dei:LegalEntityAxis
879 Entity Domain Member dei:EntityDomain
880 Omega Fund IV, L.P Member epi:OmegaFundMember
881 Disclosure of non-adjusting events after reporting period [line items] LineItems ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems
882 Exercise of pre-funded warrants Concept (Decimal) For Period epi:NumberOfPreFundedWarrantIssuedForCommonShares
883 Number of stock options granted Concept (Decimal) For Period ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
884 Exercisable price per share Concept (Monetary) For Period ifrs-full:ExercisePriceShareOptionsGranted
885 Term of exercisable stock option Concept (xbrli:durationItemType) For Period epi:TermOfExercisableStockOption

*

*